Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases
- PMID: 20569301
- DOI: 10.1111/j.1471-4159.2010.06874.x
Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases
Abstract
Cystamine has shown significant neuroprotective properties in preclinical studies of Parkinson's disease (PD) and Huntington's disease (HD). Cysteamine, its FDA-approved reduced form, is scheduled to be tested for clinical efficacy in HD patients. Here, we studied the key cystamine metabolites, namely cysteamine, hypotaurine and taurine, as well as cysteine, in order to identify which one is more distinctively responsible for the neuroprotective action of cystamine. After a single administration of cystamine (10, 50 or 200 mg/kg), naïve mice were perfused with phosphate-buffered saline (PBS) at 1, 3, 12, 24 or 48 h post-injection and brain and plasma samples were analyzed by two distinct HPLC methods. Although plasma levels remained under the detection threshold, significant increases in cysteamine brain levels were detected with the 50 and 200 mg/kg doses in mice perfused 1 and 3 h following cystamine injection. To further assess cysteamine as the candidate molecule for pre-clinical and clinical trials in PD, we evaluated its capacity to cross the blood brain barrier. Using an in situ cerebral perfusion technique, we determined that the brain transport coefficient (Clup) of cysteamine (259 μM) was 0.15 ± 0.02 μL/g/s and was increased up to 0.34 ± 0.07 μL/g/s when co-perfused in the presence of cysteine. Taken together, these results strongly suggest that cysteamine is the neuroactive metabolite of cystamine and may further support its therapeutic use in neurodegenerative diseases, particularly in HD and PD.
© 2010 The Authors. Journal Compilation © 2010 International Society for Neurochemistry.
Similar articles
-
Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.J Neurochem. 2005 Aug;94(4):1087-101. doi: 10.1111/j.1471-4159.2005.03255.x. Epub 2005 Jun 30. J Neurochem. 2005. PMID: 15992377
-
Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):380-9. doi: 10.1016/j.pnpbp.2010.11.023. Epub 2010 Nov 24. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 21111020 Review.
-
Cysteamine-related agents could be potential antidepressants through increasing central BDNF levels.Med Hypotheses. 2006;67(5):1185-8. doi: 10.1016/j.mehy.2006.05.005. Epub 2006 Jun 22. Med Hypotheses. 2006. PMID: 16797865
-
Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor.Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):193-203. doi: 10.1016/j.pnpbp.2009.11.005. Epub 2009 Nov 11. Prog Neuropsychopharmacol Biol Psychiatry. 2010. PMID: 19913065
-
Post-translational disulfide modifications in cell signaling--role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission.Free Radic Res. 2005 May;39(5):471-80. doi: 10.1080/10715760500073931. Free Radic Res. 2005. PMID: 16036322 Review.
Cited by
-
Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo.Biosci Rep. 2018 Sep 5;38(5):BSR20180691. doi: 10.1042/BSR20180691. Print 2018 Oct 31. Biosci Rep. 2018. PMID: 30054429 Free PMC article. Review.
-
Integrated electroosmotic perfusion of tissue with online microfluidic analysis to track the metabolism of cystamine, pantethine, and coenzyme A.Anal Chem. 2013 Dec 17;85(24):12020-7. doi: 10.1021/ac403005z. Epub 2013 Nov 22. Anal Chem. 2013. PMID: 24215585 Free PMC article.
-
Coated cysteamine, a potential feed additive for ruminants - An updated review.Anim Biosci. 2024 Feb;37(2):161-172. doi: 10.5713/ab.23.0245. Epub 2023 Nov 1. Anim Biosci. 2024. PMID: 37946437 Free PMC article.
-
Management dilemmas in pediatric nephrology: Cystinosis.Pediatr Nephrol. 2015 Aug;30(8):1349-60. doi: 10.1007/s00467-015-3117-3. Epub 2015 May 9. Pediatr Nephrol. 2015. PMID: 25956701
-
Stable isotope gas chromatography-tandem mass spectrometry determination of aminoethylcysteine ketimine decarboxylated dimer in biological samples.Anal Biochem. 2012 Nov 1;430(1):4-15. doi: 10.1016/j.ab.2012.07.022. Epub 2012 Jul 31. Anal Biochem. 2012. PMID: 22858756 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical